Paxil: Stronger Birth Defects Warning
Heart-Related Birth Defects Noted in 2 Studies; Cause Not Clear
Weighing Risks and Benefits
The FDA's news release notes that "the benefits of therapy may outweigh the potential risks to the fetus." "In the labeling, I think there's some important guidance for prescribers as well as patients to take note of," Renegar says.
"The labeling now advises that patients who become pregnant while they're taking [Paxil] should certainly be informed of the potential harm to the fetus," she says.
"Consideration should be given to discontinuing [Paxil] or perhaps switching to another antidepressant, unless the benefit that the mother is experiencing justifies continuing treatment," Renegar continues.
"For women who intend to become pregnant or are in their first trimester of pregnancy, other treatments and options should be considered first before initiating Paxil. So these are the recommendations that GSK and the FDA support to help put this information in a useful context for physicians as well as women to make well-informed treatment decisions," she says.
"These studies that are referenced in the new labeling are largely updated analyses from the data that was the justification for the change in September," Renegar says.
"We have worked very closely with the FDA on the data interpretation, and what the labeling should say, and how to most quickly and effectively get this out into the public," she says. "It was a collaborative effort."